Radar · Oncology in United States
Best Oncology Companies in United States
The 2665 best Oncology companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Moderna.
By Riya SenguptaFinancials
2665companies tracked
$112.1Bdisclosed funding
8unicorns
1711have raised
Ranking the best Oncology companies across the United States by disclosed equity funding and recent momentum, this directory tracks 2,665 ventures carrying a combined $112.1B in disclosed capital. That's a real number. The global oncology market sits at roughly $250.9B in 2025 and is forecast to reach $668.3B by 2034, a CAGR of 11.5% driven by rising cancer incidence and the accelerating expansion of precision medicine. Cost-containment policies are the structural headwind you'll want to watch, even as FDA draft guidance on oncology multiregional clinical trials signals tighter regulatory scaffolding ahead.
The revenue picture is more grounded than the funding headlines suggest. Across 36 validated filers, median revenue runs $11M with 4% YoY growth, but the combined pool is $9.3B and the top earners are pulling hard. Exact Sciences Corp booked $3.2B at 18% growth. BeOne Medicines hit $1.5B at 35%, and Natera pulled $697M at 39%. On the profit side, Incyte Corp earned $303M net, 36x the sector median of $9M. So when you see Grail's $2.0B raise or Century Therapeutics' $410M, I'd argue the more interesting story is who's actually converting revenue into earnings. Hot themes right now are cancer biomarkers and angiogenesis inhibitors, and the top backers include HHS, OrbiMed and RA Capital Management.
Sources & further reading
- Oncology Market Is Encouraged to Reach USD 646.33 Billion by 2032
- Oncology R&D: emerging therapies and new challenges
- Cancer's hidden cost burden strains patients and health systems: Report
FLIAR INTELLIGENCE · ONCOLOGY × UNITED STATES
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
1.7Mcombined LinkedIn audience
71%of audience held by top 3
6companies hiring publicly (12 mo)
Ranked: Best Oncology companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Moderna Developer of mRNA-based therapeutics for a wide range of diseases 82Tech top 11%Funding top 15%Market top 22%Partners top 25% All 12 signals ▾Techtop 11% Fundingtop 15% Markettop 22% Partnerstop 25% Talenttop 25% Newstop 31% Moattop 32% Patentstop 34% Globaltop 38% Innovationtop 39% Growthbottom 49% Fin. healthbottom 48% Tech: 57 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Ses Funding: Raised $2.8B across 20 rounds · 20 rounds over 14 yrs (1.4/yr) rank vs industry peers · Fliar Intelligence Index 82/100 | $2.8B | 17 mo ago | 1,312 | Robert Langer Co-Founder | Apple iCloud MailMicrosoft 365TypeScript+24 | 47 signals Earnings · Contracts · Leadership | 31 patents Patents concentrated in health & consumer products | 1 internship |
| 2 | GRAIL Developer of a screening platform for circulating tumor DNA to detect cancer 78Patents top 13%Tech top 16%News top 17%Funding top 20% All 12 signals ▾Patentstop 13% Techtop 16% Newstop 17% Fundingtop 20% Innovationtop 25% Growthtop 36% Markettop 37% Moattop 38% Partnerstop 40% Globaltop 49% Fin. healthbottom 49% Talentbottom 49% Patents: 899 patents matched (strict assignee match) · 523 filings since 2022 vs 371 in 2017-21 Tech: 51 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront rank vs industry peers · Fliar Intelligence Index 78/100 | $2.0B | 7 mo ago | 491 491 → 1,111 (+126%) · sector median +10% | Bob Ragusa Chief Executive Officer | WordPressApple iCloud MailGoogle Workspace+24 | 11 signals ▲83% Funding · Announcements · Earnings | 899 patents Liquid biopsy cancer detection via cfDNA methylation and fragment analysis | — |
| 3 | Caris Life Sciences 🦄 Developer of panomic disease profiling technologies for cancer precision medicine 78Moat top 15%Funding top 17%Product top 19%Market top 28% All 9 signals ▾Moattop 15% Fundingtop 17% Producttop 19% Markettop 28% Innovationtop 38% Growthtop 40% Newstop 43% Techtop 44% Globaltop 46% Moat: Editorial + unicorn rating 9/10 · Unicorn Funding: Raised $1.1B across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $1.1B | 14 mo ago | 1,339 | — | WordPress Site EditorCart FunctionalityWordPress+19 | 7 signals ▼22% Earnings · IPO | — | — |
| 4 | Treeline Biosciences Developer of transformative precision medicines to treat cancer 64Funding top 18%Patents top 21%Innovation top 24%Moat top 26% All 9 signals ▾Fundingtop 18% Patentstop 21% Innovationtop 24% Moattop 26% Talenttop 38% Techtop 48% Marketbottom 45% Globalbottom 40% Newsbottom 31% Funding: Raised $895M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Patents: 103 patents matched (strict assignee match) · 103 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $895M | 9 mo ago | 148 | Joshua Bilenker Co-Founder & CEO | SanityApple iCloud MailNode.js+16 | — | 103 patents Patents concentrated in chemistry & materials | — |
| 5 | Rakuten Medical Developer of a photoimmunotherapy platform for treating cancer 69Funding top 12%Moat top 24%Patents top 25%Innovation top 34% All 10 signals ▾Fundingtop 12% Moattop 24% Patentstop 25% Innovationtop 34% Growthtop 35% Newstop 39% Markettop 45% Techtop 46% Talentbottom 49% Globalbottom 42% Funding: Raised $874M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 150 patents rank vs industry peers · Fliar Intelligence Index 69/100 | $874M | 11 mo ago | 110 110 → 129 (+17%) · sector median +10% | Hiroshi Mikitani Chairman & CEO | WordPressApple iCloud MailMySQL+27 | — | 150 patents Photodynamic therapy delivery devices and catheter-based drug administration technologies | — |
| 6 | Summit Developer of therapeutics for oncology and rare diseases 22Partners top 31%Funding top 33%Product top 35%News top 37% All 13 signals ▾Partnerstop 31% Fundingtop 33% Producttop 35% Newstop 37% Techtop 45% Growthbottom 43% Moatbottom 43% Marketbottom 42% Talentbottom 41% Globalbottom 37% Patentsbottom 30% Innovationbottom 26% Fin. healthbottom 22% Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals Funding: Raised $713M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $713M | 7 mo ago | 99 | Maky Zanganeh CEO | WordPress Block EditorWordPressMySQL+18 | 11 signals ▼45% M&A · Contracts · Acquisition | 13 patents Digital media submission, processing, and distribution platforms for online content management. | — |
| 7 | Guardant Health Developer of digital sequencing technology for cancer detection 90Patents top 14%Funding top 15%Innovation top 17%Moat top 19% All 13 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Moattop 19% Markettop 23% Techtop 23% Newstop 29% Growthtop 30% Producttop 35% Fin. healthtop 36% Partnerstop 41% Globaltop 45% Talenttop 46% Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 90/100 | $557M | 7 mo ago | 1,351 | Amirali Talasaz Co-founder and Co-Chief Executive Officer | WordPressBugHerdApple iCloud Mail+25 | 25 signals ▲56% Earnings · Announcements · Regulatory | 996 patents Liquid biopsy cfDNA sequencing and analysis for cancer detection and monitoring | 1 launch · 1 partnership |
| 8 | Odyssey Developer of immunotherapeutics for immunological and cancer diseases 74Funding top 12%Growth top 13%Talent top 28%Moat top 31% All 7 signals ▾Fundingtop 12% Growthtop 13% Talenttop 28% Moattop 31% Techbottom 46% Marketbottom 45% Globalbottom 39% Funding: Raised $503M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Growth: Headcount 50 → 108 (+116%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $503M | 12 mo ago | 108 108 → 118 (+9%) · sector median +10% | Paul-Albert König Co-Founder and Sr. Director Biology | WordPressApple iCloud MailMicrosoft 365+22 | — | — | — |
| 9 | Lyell Immunopharma Developer of CAR- T therapy for cancer treatment 45Patents top 14%Innovation top 21%Funding top 24%Talent top 28% All 11 signals ▾Patentstop 14% Innovationtop 21% Fundingtop 24% Talenttop 28% Techtop 30% Moatbottom 46% Globalbottom 42% Marketbottom 32% Growthbottom 32% Newsbottom 23% Fin. healthbottom 18% Patents: 163 patents matched (strict assignee match) · 154 filings since 2022 vs 9 in 2017-21 Innovation: 163 patents (top 13% of patent-holders) · 154 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $493M | 10 mo ago | 224 224 → 233 (+4%) · sector median +10% | Stan Riddell Co-Founder | WordPressMySQLPHP+16 | — | 163 patents Patents concentrated in chemistry & materials | — |
| 10 | Agenusbio Developer of immunotherapies to treat cancer 60Funding top 20%Tech top 34%Product top 35%Market top 37% All 11 signals ▾Fundingtop 20% Techtop 34% Producttop 35% Markettop 37% Moattop 44% Partnerstop 45% Fin. healthtop 48% Growthtop 50% Newsbottom 47% Talentbottom 40% Globalbottom 39% Funding: Raised $441M across 12 rounds · 12 rounds over 17 yrs (0.7/yr) Tech: 41 technologies across 6/8 capability areas · Cloud: Cloudflare, Fastly rank vs industry peers · Fliar Intelligence Index 60/100 | $441M | 12 mo ago | 533 | Garo Armen Chairman & CEO | WordPressMySQLMariaDB+19 | 10 signals ▼74% Earnings · Announcements · Leadership | — | — |
| 11 | Century Therapeutics Developer of therapeutics for the treatment of autoimmune diseases and cancer 72Funding top 17%Growth top 30%Fin. health top 34%Market top 40% All 8 signals ▾Fundingtop 17% Growthtop 30% Fin. healthtop 34% Markettop 40% Moattop 42% Techbottom 45% Globalbottom 39% Newsbottom 23% Funding: Raised $410M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Growth: Revenue +1557% YoY · 1 acquisition/expansion move in 24 mo rank vs industry peers · Fliar Intelligence Index 72/100 | $410M | 5 mo ago | 94 94 → 118 (+26%) · sector median +10% | — | DrupalPHPAmazon Web Services+20 | — | — | 1 award |
| 12 | TORL BioTherapeutics Developer of antibody-based therapeutics for the treatment of cancer 37Funding top 16%Moat top 31%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 16% Moattop 31% Talentbottom 49% Marketbottom 40% Globalbottom 29% Funding: Raised $350M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 37/100 | $350M | 8 mo ago | — | Mark Attanasio Co-Founder | — | — | — | — |
| 13 | Delfi Diagnostics Provider of DNA sequencing for cancer detection 67Funding top 17%Patents top 24%AI top 28%Moat top 28% All 11 signals ▾Fundingtop 17% Patentstop 24% AItop 28% Moattop 28% Innovationtop 32% Talenttop 42% Growthtop 48% Marketbottom 49% Techbottom 47% Globalbottom 36% Newsbottom 33% Funding: Raised $332M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 52 patents matched (strict assignee match) · 52 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $332M | 6 mo ago | 197 | Victor Velculescu Founder and Board of Directors | WordPressApple iCloud MailMySQL+16 | — | 52 patents Non-invasive cancer detection and monitoring via cell‑free DNA fragmentation profiling | 1 job opening · 1 partnership · 3 awards |
| 14 | HistoSonics Ultrasound-based tissue ablation 69Funding top 17%Patents top 17%Innovation top 19%News top 23% All 11 signals ▾Fundingtop 17% Patentstop 17% Innovationtop 19% Newstop 23% Producttop 26% Moattop 26% Growthtop 30% Techtop 46% Talentbottom 49% Marketbottom 42% Globalbottom 40% Funding: Raised $316M across 11 rounds · 11 rounds over 12 yrs (0.9/yr) Patents: 168 patents matched (strict assignee match) · 108 filings since 2022 vs 24 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $316M | 8 mo ago | 56 | Mike Blue President and CEO | WordPressMySQLSalesforce+33 | 8 signals ▲100% Funding · M&A · Capital raise | 168 patents Image-guided therapeutic ultrasound (histotripsy) systems for non-invasive tissue ablation | 1 award |
| 15 | Parabilis Medicines Developer of peptide therapeutics for the treatment of severe diseases 55Funding top 13%Growth top 35%Moat top 37%Patents top 39% All 9 signals ▾Fundingtop 13% Growthtop 35% Moattop 37% Patentstop 39% Innovationtop 43% Globaltop 50% Talentbottom 49% Techbottom 43% Marketbottom 40% Funding: Raised $305M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $305M | 5 mo ago | — | Mathai Mammen CEO | WordPressApple iCloud MailMySQL+19 | — | 11 patents Design and synthesis of stapled peptide therapeutics for targeted drug delivery | — |
| 16 | Orca Bio 🦄 Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders 74Funding top 18%Growth top 26%Moat top 26%Talent top 38% All 8 signals ▾Fundingtop 18% Growthtop 26% Moattop 26% Talenttop 38% Techtop 40% Markettop 42% Globalbottom 37% Newsbottom 18% Funding: Raised $300M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) Growth: Headcount 39 → 66 (+69%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $300M | 5 mo ago | 66 | Jeroen Bekaert Co-Founder & COO | WordPressApple iCloud MailGoogle Workspace+29 | — | — | 1 expansion |
| 17 | Celularity Developer of allogeneic cell therapies to treat multiple diseases 67Funding top 18%Patents top 30%Fin. health top 38%Moat top 38% All 11 signals ▾Fundingtop 18% Patentstop 30% Fin. healthtop 38% Moattop 38% Innovationtop 39% Growthtop 39% Newstop 39% Markettop 40% Techtop 48% Talentbottom 49% Globalbottom 40% Funding: Raised $290M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) Patents: 488 patents matched (strict assignee match) · 135 filings since 2022 vs 309 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $290M | 5 mo ago | 225 225 → 145 (-36%) · sector median +10% | Robert Hariri Chairman & CEO | WordPressMySQLPHP+22 | 8 signals ▼38% Earnings · Funding · Announcements | 488 patents Placental-derived extracellular matrix and engineered immune cell therapies for regenerative medicine | — |
| 18 | Sirnaomics Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease 80Patents top 14%Funding top 15%Innovation top 17%Growth top 28% All 9 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Growthtop 28% Moattop 35% Markettop 46% Talentbottom 49% Globalbottom 48% Newsbottom 21% Patents: 277 patents matched (strict assignee match) · 191 filings since 2022 vs 63 in 2017-21 Funding: Raised $267M across 14 rounds · 14 rounds over 19 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $267M | 9 mo ago | 88 | Patrick Lu President and CEO | — | — | 277 patents siRNA therapeutics and nanoparticle delivery systems for cancer and viral diseases | 1 launch |
| 19 | BlossomHill Therapeutics Provider of the drug for the treatment of oncology and autoimmune disorders 55Funding top 20%Patents top 21%Innovation top 23%Moat top 26% All 7 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 23% Moattop 26% Newsbottom 42% Globalbottom 42% Marketbottom 34% Funding: Raised $260M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Patents: 133 patents matched (strict assignee match) · 133 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $260M | 6 mo ago | 14 | — | — | — | 133 patents Patents concentrated in chemistry & materials | 3 job openings |
| 20 | Terremoto Developer of small-molecule therapeutics for cancer treatment 60Funding top 15%Talent top 28%Moat top 31%Growth top 35% All 7 signals ▾Fundingtop 15% Talenttop 28% Moattop 31% Growthtop 35% Techtop 49% Marketbottom 41% Globalbottom 36% Funding: Raised $250M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 60/100 | $250M | 2 mo ago | 35 | Matt Jacobson Co-Founder | WordPressBugHerdZendesk+24 | — | — | — |
| 21 | CytoDyn Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection 32Funding top 17%Growth top 35%Patents top 36%Innovation top 44% All 10 signals ▾Fundingtop 17% Growthtop 35% Patentstop 36% Innovationtop 44% Moatbottom 49% Globalbottom 36% Techbottom 35% Newsbottom 26% Marketbottom 25% Fin. healthbottom 24% Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 32/100 | $250M | 3 mo ago | 12 12 → 23 (+92%) · sector median +10% | — | Apple iCloud MailMicrosoft 365Bootstrap+8 | — | 107 patents CCR5-targeted biologics for HIV, cancer, NAFLD/NASH and immune‑modulating therapies | 1 partnership |
| 22 | Iambic Therapeutics Provider of AI-driven drug discovery platform for the treatment of cancer 60Funding top 15%AI top 26%Moat top 31%Talent top 38% All 9 signals ▾Fundingtop 15% AItop 26% Moattop 31% Talenttop 38% Growthtop 45% Marketbottom 43% Newsbottom 43% Techbottom 40% Globalbottom 39% Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) AI: Classified as an AI company · Product described with: ai driven, ai-driven rank vs industry peers · Fliar Intelligence Index 60/100 | $206M | 2 mo ago | 50 | Fred Manby Co-Founder & CTO | WebflowApple iCloud MailMicrosoft 365+13 | — | — | — |
| 23 | Solve Therapeutics Developer of antibody-based therapies targeting tumor-specific antigens for cancer treatment 55Funding top 16%Moat top 40%Global top 45%Market bottom 49% All 5 signals ▾Fundingtop 16% Moattop 40% Globaltop 45% Marketbottom 49% Talentbottom 49% Funding: Raised $195M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Soonicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 55/100 | $195M | 7 mo ago | — | Dave Johnson Founder & CEO | — | — | — | — |
| 24 | NextCure Developer of next-generation immuno-oncology-based drugs 69News top 21%Funding top 23%Patents top 25%Moat top 26% All 11 signals ▾Newstop 21% Fundingtop 23% Patentstop 25% Moattop 26% Growthtop 30% Innovationtop 32% Fin. healthtop 43% Markettop 44% Partnerstop 45% Techbottom 46% Globalbottom 42% News: 7 BI events in 12 mo (of 19 tracked, 5 types) · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo Funding: Raised $175M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 69/100 | $175M | 7 mo ago | 87 | — | WordPressDrupalMySQL+24 | 7 signals Announcements · Earnings · Funding | 77 patents Therapeutic antibodies and ADCs targeting novel immune checkpoints for cancer treatment | — |
| 25 | Third Arc Bio Developer of therapetics for cancer and immunological diseases 37Funding top 20%Talent top 38%Moat bottom 48%Tech bottom 47% All 7 signals ▾Fundingtop 20% Talenttop 38% Moatbottom 48% Techbottom 47% Globalbottom 36% Marketbottom 32% Newsbottom 18% Funding: Raised $165M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $165M | 4 mo ago | — | Sanjaya Singh Founder & Chief Scientific Officer | GSAPReactGatsby+15 | — | — | — |
| 26 | Tango Therapeutics Developer of drugs for the treatment of cancer 72Funding top 21%News top 21%Growth top 24%Talent top 33% All 10 signals ▾Fundingtop 21% Newstop 21% Growthtop 24% Talenttop 33% Fin. healthtop 41% Techtop 44% Markettop 45% Partnerstop 45% Moatbottom 49% Globalbottom 37% Funding: Raised $165M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) News: 17 BI events in 12 mo (of 35 tracked, 6 types) · +240% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $165M | 7 mo ago | 140 140 → 157 (+12%) · sector median +10% | Barbara Weber Md President and CEO | DrupalPHPZURB Foundation+21 | 17 signals ▲240% Earnings · Funding · Leadership | — | — |
| 27 | Senti Bio Developer of cell and gene therapies for patients living with incurable diseases 45Product top 14%Funding top 21%Talent top 22%Tech top 32% All 11 signals ▾Producttop 14% Fundingtop 21% Talenttop 22% Techtop 32% Innovationtop 34% Newsbottom 43% Moatbottom 43% Growthbottom 39% Globalbottom 39% Marketbottom 32% Fin. healthbottom 20% Product: 4 distinct product lines · Company stage: Public Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $158M | 1 mo ago | 122 | Jim Collins Co-Founder | DrupalPHPSalesforce+24 | 3 signals ▼75% Earnings · Announcements | — | — |
| 28 | Precision BioSciences Developer of gene editing therapies to treat rare genetic diseases 57Product top 19%Funding top 21%Moat top 32%Patents top 36% All 11 signals ▾Producttop 19% Fundingtop 21% Moattop 32% Patentstop 36% Newstop 38% Markettop 39% Techtop 41% Innovationtop 42% Growthbottom 47% Globalbottom 42% Fin. healthbottom 39% Product: 3 distinct product lines · Company stage: Public Funding: Raised $136M across 9 rounds · 9 rounds over 16 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $136M | 3 mo ago | 236 | — | DrupalApple iCloud MailMicrosoft 365+23 | 3 signals ▲50% Regulatory · Earnings · Capital raise | 68 patents Therapeutic genome editing using engineered meganucleases and engineered T‑cell therapies | 1 launch |
| 29 | CREATE Medicines Developer of messenger ribonucleic acid therapies for immune cell programming 50Funding top 20%Patents top 41%Innovation top 47%Talent bottom 49% All 5 signals ▾Fundingtop 20% Patentstop 41% Innovationtop 47% Talentbottom 49% Globalbottom 35% Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $122M | 1 mo ago | — | Daniel Getts Co-Founder & CEO | — | — | 18 patents Therapeutic chimeric fusion proteins and gene/miRNA delivery platforms for drug development | — |
| 30 | Aprea Developer of small molecule therapeutics targeting tumor suppressor proteins 40Funding top 18%Growth top 30%News top 38%Moat top 48% All 7 signals ▾Fundingtop 18% Growthtop 30% Newstop 38% Moattop 48% Globalbottom 42% Techbottom 35% Marketbottom 25% Funding: Raised $113M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $113M | 6 mo ago | 13 | — | WordPressMySQLPHP+15 | 4 signals ▲33% Earnings · Announcements · Funding | — | — |
| 31 | Adela Developer of a platform for detection of cancer 57Funding top 22%Moat top 31%Patents top 38%Talent top 38% All 8 signals ▾Fundingtop 22% Moattop 31% Patentstop 38% Talenttop 38% Markettop 46% Innovationtop 49% Globalbottom 40% Newsbottom 22% Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents rank vs industry peers · Fliar Intelligence Index 57/100 | $109M | 2 mo ago | 62 | Manish Agarwal Co-Founder | — | — | 15 patents Liquid biopsy nucleic acid extraction and sequencing library preparation technologies | 1 job opening · 1 partnership |
| 32 | Atavistik Developer of allosteric therapeutics for precision oncology and rare diseases 50Funding top 19%Talent top 28%Moat top 31%Market bottom 42% All 6 signals ▾Fundingtop 19% Talenttop 28% Moattop 31% Marketbottom 42% Globalbottom 36% Newsbottom 33% Funding: Raised $100M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $100M | 3 mo ago | 33 | Ralph DeBerardinis Co-Founder | — | — | — | — |
| 33 | Vyriad Developer of oncolytic-virus-based immunotherapies for cancer treatment 50Patents top 20%Funding top 21%Innovation top 25%Moat top 32% All 7 signals ▾Patentstop 20% Fundingtop 21% Innovationtop 25% Moattop 32% Techbottom 43% Globalbottom 37% Marketbottom 36% Patents: 70 patents matched (strict assignee match) · 56 filings since 2022 vs 14 in 2017-21 Funding: Raised $100M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $100M | 5 mo ago | 37 | — | WordPressMySQLPHP+18 | — | 70 patents Engineered rhabdoviral vectors for cancer immunotherapy and viral antibody diagnostics | — |
| 34 | Karyopharm Biopharmaceutical company focused on developing and commercializing innovative cancer therapies 69Funding top 17%News top 26%Market top 32%Tech top 34% All 9 signals ▾Fundingtop 17% Newstop 26% Markettop 32% Techtop 34% Moattop 42% Fin. healthtop 43% Talenttop 45% Growthbottom 49% Globalbottom 49% Funding: Raised $98.4M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) News: 30 BI events in 12 mo (of 119 tracked, 8 types) · +114% YoY rank vs industry peers · Fliar Intelligence Index 69/100 | $98M | 2 mo ago | 325 325 → 320 (-2%) · sector median +10% | Michael Kauffman Cofounder | WordPressApple iCloud MailMySQL+27 | 30 signals ▲114% Announcements · Earnings · Funding | — | — |
| 35 | Bonum Therapeutics Manufacturer of cytokine based drugs 45Funding top 22%Talent bottom 49%Tech bottom 45%Global bottom 43% All 5 signals ▾Fundingtop 22% Talentbottom 49% Techbottom 45% Globalbottom 43% Marketbottom 36% Funding: Raised $93.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 45/100 | $93M | 2 mo ago | 54 | John Mulligan Founder & CEO | WordPressMySQLPHP+21 | — | — | — |
| 36 | TEMPEST THERAPEUTICS Developing targeted, immune-mediated oral cancer therapies for broad patient benefit 21Funding top 28%News top 36%Growth top 42%Tech top 49% All 9 signals ▾Fundingtop 28% Newstop 36% Growthtop 42% Techtop 49% Moatbottom 43% Talentbottom 41% Globalbottom 39% Marketbottom 23% Fin. healthbottom 13% Funding: Raised $88.2M across 4 rounds · 4 rounds over 15 yrs (0.3/yr) News: 19 BI events in 12 mo (of 57 tracked, 7 types) · +6% YoY rank vs industry peers · Fliar Intelligence Index 21/100 | $88M | 2 mo ago | 19 | Stephen B Chief Executive Officer | DrupalPHPparticles.js+25 | 19 signals Earnings · Funding · M&A | — | — |
| 37 | TRexBio Developer of therapeutics for immunology and cancer 45Funding top 20%Moat top 31%News top 46%Talent bottom 49% All 6 signals ▾Fundingtop 20% Moattop 31% Newstop 46% Talentbottom 49% Marketbottom 47% Globalbottom 36% Funding: Raised $85.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 45/100 | $85M | 4 mo ago | 65 | Johnston Erwin CEO | — | — | — | — |
| 38 | Crossbow Developer of antibody therapies for cancer treatment 42Funding top 21%Moat top 36%News top 38%Talent top 38% All 8 signals ▾Fundingtop 21% Moattop 36% Newstop 38% Talenttop 38% Innovationtop 48% Patentsbottom 49% Globalbottom 39% Marketbottom 35% Funding: Raised $80.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 21 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $80M | 3 mo ago | 24 | Geraldine Paulus Co-Founder | — | 3 signals Funding | 21 patents High‑precision MEMS inertial sensors and power‑efficient wireless tracking technologies | — |
| 39 | ClearNote Health Developer of non-invasive cancer detection methods 40Moat top 22%Funding top 36%Market top 50%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 36% Markettop 50% Talentbottom 49% Globalbottom 36% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $70M | 0 mo ago | 45 | Dave Mullarkey Chief Executive Officer | — | — | — | — |
| 40 | CASI Pharmaceuticals Developer of therapeutics for the treatment of cancer 60Product top 19%Funding top 26%Growth top 36%Innovation top 38% All 10 signals ▾Producttop 19% Fundingtop 26% Growthtop 36% Innovationtop 38% Fin. healthtop 43% Markettop 46% Moatbottom 49% Globalbottom 44% Newsbottom 41% Techbottom 33% Product: 3 distinct product lines · Company stage: Public Funding: Raised $69.5M across 5 rounds · 5 rounds over 20 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $69M | 5 mo ago | 234 | — | DudaNginxSnowplow Analytics+12 | 3 signals ▼50% Leadership | — | — |
| 41 | Verismo Therapeutics Developer of CAR-T cell therapies for cancer 16Funding top 32%Moat top 39%Tech bottom 43%Global bottom 38% All 6 signals ▾Fundingtop 32% Moattop 39% Techbottom 43% Globalbottom 38% Marketbottom 25% Newsbottom 21% Funding: Raised $50.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 16/100 | $50M | 1 mo ago | 9 | — | WordPressMySQLPHP+18 | — | — | 1 job opening · 1 partnership · 1 award |
| 42 | LTZ Therapeutics Developer of immunotherapies to treat cancer and other diseases 35Funding top 26%Moat top 39%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 26% Moattop 39% Talentbottom 49% Marketbottom 40% Globalbottom 36% Funding: Raised $47.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 35/100 | $47M | 1 mo ago | 23 | Martin Treder Co-Founder | — | — | — | 2 job openings |
| 43 | Primmune Therapeutics Developer of immunotherapies for treating cancer 42Funding top 21%Talent top 28%Product top 35%Innovation top 38% All 8 signals ▾Fundingtop 21% Talenttop 28% Producttop 35% Innovationtop 38% Moattop 39% Techbottom 40% Globalbottom 36% Marketbottom 26% Funding: Raised $46.8M across 8 rounds · 8 rounds over 6 yrs (1.3/yr) Talent: Analyst team rating 4/5 · 4 named leaders on record rank vs industry peers · Fliar Intelligence Index 42/100 | $47M | 4 mo ago | 9 | Stephen Webber Co-Founder | — | — | — | — |
| 44 | Artelo Biosciences Modifying lipid-signaling pathways to improve cancer treatments 53Funding top 17%Growth top 20%News top 23%Product top 24% All 9 signals ▾Fundingtop 17% Growthtop 20% Newstop 23% Producttop 24% Innovationtop 43% Talenttop 46% Techbottom 46% Globalbottom 38% Marketbottom 24% Funding: Raised $39.9M across 13 rounds · 13 rounds over 8 yrs (1.6/yr) Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $40M | 2 mo ago | 7 | Greg Gorgas CEO & President | WordPressMySQLPHP+16 | 8 signals ▲700% Leadership · Board · Funding | — | 1 partnership |
| 45 | Incyclix Bio A next-generation cell cycle control company advancing precision treatments for cancer 21Funding top 25%Talent top 28%Moat top 39%Tech bottom 31% All 6 signals ▾Fundingtop 25% Talenttop 28% Moattop 39% Techbottom 31% Globalbottom 29% Marketbottom 20% Funding: Raised $30.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $30M | 2 mo ago | 6 | Patrick Roberts Co-Founder & CEO | WordPressMySQLPHP+14 | — | — | — |
| 46 | Kanvas Biosciences Provider of imaging solutions for microbial research and infectious diseases 27Funding top 27%Talent top 38%Global bottom 38%Moat bottom 38% All 5 signals ▾Fundingtop 27% Talenttop 38% Globalbottom 38% Moatbottom 38% Marketbottom 27% Funding: Raised $29.5M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 27/100 | $30M | 1 mo ago | 10 | Iwijn De Vlaminck Co-Founder | — | — | — | 1 expansion |
| 47 | Athos Therapeutics Developer of AI-based therapeutics for treating autoimmune diseases 35AI top 35%Funding top 36%Talent bottom 49%Moat bottom 45% All 6 signals ▾AItop 35% Fundingtop 36% Talentbottom 49% Moatbottom 45% Marketbottom 32% Globalbottom 25% AI: Product described with: ai-based, machine learning Funding: Raised $28.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $28M | 2 mo ago | 18 | Dimitrios Iliopoulos Co-founder | — | — | — | — |
| 48 | OncoSynergy Developer of resistance mechanism inhibitors to treat cancer 11Funding top 28%Moat top 32%Patents bottom 48%Global bottom 42% All 6 signals ▾Fundingtop 28% Moattop 32% Patentsbottom 48% Globalbottom 42% Innovationbottom 33% Marketbottom 18% Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 11/100 | $27M | 1 mo ago | 3 | — | — | — | 26 patents Patents concentrated in chemistry & materials | — |
| 49 | Cue Biopharma Precision immunotherapies to transform patients' lives by selectively modulating the immune system 67Innovation top 16%Patents top 16%News top 28%Moat top 29% All 11 signals ▾Innovationtop 16% Patentstop 16% Newstop 28% Moattop 29% Growthtop 31% Partnerstop 32% Fundingtop 36% Fin. healthtop 37% Marketbottom 49% Globalbottom 35% Techbottom 32% Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21 Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $26M | 1 mo ago | 51 51 → 39 (-24%) · sector median +10% | — | WordPress Block EditorWordPressMySQL+15 | 16 signals ▲45% Board · Leadership · Earnings | 491 patents T-cell engaging biologics for immune modulation and B-cell depletion therapies | — |
| 50 | Enveric Developer of small-molecule therapeutics for the treatment of neuropsychiatric disorders 42Funding top 29%News top 30%Growth top 31%Talent bottom 49% All 9 signals ▾Fundingtop 29% Newstop 30% Growthtop 31% Talentbottom 49% Fin. healthbottom 42% Techbottom 38% Globalbottom 38% Marketbottom 36% Moatbottom 36% Funding: Raised $26.4M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) News: 15 BI events in 12 mo (of 35 tracked, 3 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 42/100 | $26M | 2 mo ago | 25 | Joseph Tucker CEO | WordPressMySQLPHP+18 | 15 signals ▲200% Earnings · Funding | — | — |
Top 12 Oncology companies in United States
#1
Public · Menlo Park, California · founded 2016 · 491 employees$2Braised▾
Public · Menlo Park, California · founded 2016 · 491 employees
Developer of a screening platform for circulating tumor DNA to detect cancer. The company is developing a test called "Galleri" a pan-cancer screening test by measuring circulating nucleic acids in the blood. Its proprietary platform uses the ultra-deep sequencing technique to measure levels of circulating tumor DNA in the patient's blood.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Patents
top 13%Tech
top 16%News
top 17%Funding
top 20%Innovation
top 25%Growth
top 36%Patents: 899 patents matched (strict assignee match) · 523 filings since 2022 vs 371 in 2017-21 · Latest publication 2026
Tech: 51 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront · Devops: Nginx
News: 11 BI events in 12 mo (of 75 tracked, 14 types) · +83% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 113k LinkedIn followers — 6.7% of this cohort's audience
Funding rounds
- Oct 2025Post IPO$325M
- Nov 2019Series D$390M
- May 2018Series C$300M
- Jun 2017Series B—
Founders & team
Investors
PSP Investments, CPP Investments, Illumina, Arch Venture Partners, Johnson & Johnson Innovation, McKesson Ventures
Tech stack
Amazon CloudfrontAmazon S3Amazon SesAmazon Web ServicesApolloApple Icloud Mail
#2
Public · San Francisco, California · founded 2016 · 122 employees$158Mraised▾
Public · San Francisco, California · founded 2016 · 122 employees
Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Product
top 14%Funding
top 21%Talent
top 22%Tech
top 32%Innovation
top 34%News
bottom 43%Product: 4 distinct product lines · Company stage: Public
Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) · Last round Post IPO (May 2026)
Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 12k LinkedIn followers
Funding rounds
- May 2026Post IPO$40M
- Dec 2024Post IPO$37.6M
- Dec 2024Post IPO$10M
- Jun 2024Grant (prize money)$8M
Founders & team
Investors
Matrix Partners China, Mirae Asset, Ridgeback Capital Management, Lux Capital, Gaingels, KB Investment
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAddthisAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#3
Series C · San Francisco, California · founded 2021 · 35 employees$250Mraised▾
Series C · San Francisco, California · founded 2021 · 35 employees
Developer of small-molecule therapeutics for cancer treatment. It provides a lysine-targeted covalency platform to develop therapies against known drug targets for oncology.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 15%Talent
top 28%Moat
top 31%Growth
top 35%Tech
top 49%Market
bottom 41%Funding: Raised $250M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series C (Apr 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers
Funding rounds
- Apr 2026Series C$108M
- Nov 2023Series B$175M
- May 2022Series A$75M
Founders & team
Investors
Orbimed, Third Rock Ventures, EcoR1, Novo Holdings, Cormorant Capital, RA Capital Management
Tech stack
All In One SeoAmazon Web ServicesApple Icloud MailBugherdCdnjsCloudflare
#4
Series C · San Diego, California · founded 2019 · 50 employees$206.2Mraised▾
Series C · San Diego, California · founded 2019 · 50 employees
Provider of AI-driven drug discovery platform for the treatment of cancer. It offers an AI driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1 a potential first-in-class selective dual CDK2/4 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell cycle driven cancers.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 15%AI
top 26%Moat
top 31%Talent
top 38%Growth
top 45%Market
bottom 43%Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) · Last round Series C (Apr 2026)
AI: Classified as an AI company · Product described with: ai driven, ai-driven
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Apr 2026Series C$27.8M
- Nov 2025Series C$100M
- Apr 2024Series B$50M
- Oct 2023Series B$103.2M
Founders & team
Investors
Ascenta Capital, Abingworth, Nvidia, Illumina Ventures, Shanda, Catalio Capital Management
Tech stack
Apple Icloud MailCloudflareDocusignGoogle Font ApiGoogle Hosted LibrariesHsts
#5
Public · Vancouver, Washington · founded 2002 · 12 employees$249.7Mraised▾
Public · Vancouver, Washington · founded 2002 · 12 employees
Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection. It offers lead candidate, PRO 140,for HIV with demonstrated antiviral activity in men. PRO 140 blocks the HIV co-receptor CCR5 on T-cells that prevent viral entry.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 17%Growth
top 35%Patents
top 36%Innovation
top 44%Moat
bottom 49%Global
bottom 36%Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) · Last round Post IPO (Mar 2026)
Growth: Fresh capital in last 24 mo
Patents: 107 patents matched (strict assignee match) · 25 filings since 2022 vs 49 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Natera) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$17.5M
- Jan 2026Post IPO$18.6M
- Apr 2022Post IPO$1.9M
- Dec 2021Post IPO$11.4M
Investors
Cool Blue Capital, Centrecourt Asset Management, 4-Good Ventures
Tech stack
Amazon Web ServicesApache Http ServerApple Icloud MailBootstrapFancyboxGoogle Analytics
#6
Public · Philadelphia, Pennsylvania · founded 2018 · 94 employees$410Mraised▾
Public · Philadelphia, Pennsylvania · founded 2018 · 94 employees
Developer of therapeutics for the treatment of autoimmune diseases and cancer. The company's iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 17%Growth
top 30%Fin. health
top 34%Market
top 40%Moat
top 42%Tech
bottom 45%Funding: Raised $410M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Post IPO (Jan 2026)
Growth: Revenue +1557% YoY · 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
Fin. health: Revenue ~$109M (FY2024) · Net margin -19.8% · Revenue +1557% YoY
Audience (LinkedIn): 27k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Jan 2026Post IPO$135M
- Apr 2024Post IPO$60M
- Mar 2021Series C$160M
- Jul 2019Series C$250M
Investors
Bain Capital Life Sciences, Adage Capital Management, Octagon Capital Advisors, Superstring Capital Management, Casdin Capital, Boxer Capital
#7
Series B · Cambridge, Massachusetts · founded 2019$122Mraised▾
Series B · Cambridge, Massachusetts · founded 2019
Developer of messenger ribonucleic acid therapies for immune cell programming. These therapies utilize lipid nanoparticle delivery systems to modify immune cells directly within the body. The technology targets specific cell types to address conditions related to oncology and autoimmunity. The approach focuses on the expression of chimeric antigen receptors to facilitate immune responses against disease targets.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 20%Patents
top 41%Innovation
top 47%Talent
bottom 49%Global
bottom 35%Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (May 2026)
Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Innovation: 18 patents (top 74% of patent-holders) · 17 filings since 2022 vs 1 in 2017-21
Funding rounds
- May 2026Series B$122M
Founders & team
Investors
Newpath Partners, Hatteras Venture Partners, Arch Venture Partners, Alexandria Venture Investments
#8
Public · Redwood City, California · founded 2012 · 1351 employees$557.5Mraised▾
Public · Redwood City, California · founded 2012 · 1351 employees
Developer of digital sequencing technology for cancer detection. The product Guardant360 offers real-time, biopsy-free tumor sequencing for the analysis and identification of tumor-associated treatment options. Also, it has developed analytical tools, including a tumor response map and a mobile-enabled physician portal.
Fliar Intelligence Index™ 90how this company ranks against its industry peers
Patents
top 14%Funding
top 15%Innovation
top 17%Moat
top 19%Market
top 23%Tech
top 23%Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 · Latest publication 2026
Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) · Last round Post IPO (Nov 2025)
Innovation: 996 patents (top 3% of patent-holders) · 615 filings since 2022 vs 346 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 275k LinkedIn followers — 16.5% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Cancer Research UK Science and Innovation and The Royal Marsden NHS Foundation Trust) announced in 12 mo
Funding rounds
- Nov 2025Post IPO$350M
- Nov 2020Post IPO$1B
- Aug 2017Series E$360M
- Jan 2016Series D$100M
Founders & team
Investors
Orbimed, Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Formation 8, Heritage Group
Tech stack
Amazon Web ServicesAosApache Http ServerApple Icloud MailBootstrapBugherd
#9
Series A · San Francisco, California · founded 2021 · 62 employees$108.5Mraised▾
Series A · San Francisco, California · founded 2021 · 62 employees
Developer of a platform for detection of cancer. The company has developed a blood test for genome-wide methylation analysis technology to detect kidney cancer and intracranial brain tumors. It allows distinguishing the informative methylated regions of the genome from non-informative regions and targets for sequencing.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 22%Moat
top 31%Patents
top 38%Talent
top 38%Market
top 46%Innovation
top 49%Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series A (Apr 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents · Soonicorn
Patents: 15 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Accounts Payable Clerk
Activity (LinkedIn): 1 partnerships announced in 12 mo
Funding rounds
- Apr 2026Series A$5M
- Jun 2025Series A$25.4M
- Jul 2023Series A$48.5M
- Jun 2021Series A$60M
Founders & team
Investors
F-Prime Capital, Orbimed, Deerfield, Decheng Capital, RA Capital Management, LabCorp
#10
Public · Menlo Park, California · founded 2003 · 99 employees$713Mraised▾
Public · Menlo Park, California · founded 2003 · 99 employees
Developer of therapeutics for oncology and rare diseases. It offers Ivonescimab which combines the effects of immunotherapy via a blockade of PD-1 with the anti-VEGF effect for the treatment of non-small cell lung cancer.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Partners
top 31%Funding
top 33%Product
top 35%News
top 37%Tech
top 45%Growth
bottom 43%Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals
Funding: Raised $713M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) · Last round Post IPO (Oct 2025)
Product: 0 product launch events in 12 mo, 1 the year before · Company stage: Public
Audience (LinkedIn): 58k LinkedIn followers — 3.5% of this cohort's audience
Funding rounds
- Oct 2025Post IPO$228M
- Sep 2024Post IPO$235M
- Jun 2024Post IPO$200M
- Nov 2020Post IPO$50M
Founders & team
Investors
Akeso
Tech stack
CloudflareFancyboxGodaddyGoogle Font ApiHstsJquery
#11
Public · Durham, North Carolina · founded 2006 · 236 employees$135.7Mraised▾
Public · Durham, North Carolina · founded 2006 · 236 employees
Developer of gene editing therapies to treat rare genetic diseases. The company utilizes novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination. The company's pipeline include therapies for Hepatitis B, duchenne muscular dystrophy, and more.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Product
top 19%Funding
top 21%Moat
top 32%Patents
top 36%News
top 38%Market
top 39%Product: 3 distinct product lines · Company stage: Public
Funding: Raised $136M across 9 rounds · 9 rounds over 16 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Moat: Editorial + unicorn rating 6/10 · IP moat: 68 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Mar 2026Post IPO$7.5M
- Jun 2022Post IPO$75M
- Mar 2019Conventional Debt$39.5M
- Jun 2018Series B$110M
Investors
NIST, NIH, North Carolina, Treasury, VenBio, Baxter
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#12
Series D · San Diego, California · founded 2016 · 45 employees$70Mraised▾
Series D · San Diego, California · founded 2016 · 45 employees
Developer of non-invasive cancer detection methods. It offers a 5-hydroxymethylcytosine-based epigenomic platform and cell-free DNA-based assays to measure biological changes in cells and detect cancers with high mortality rates when they respond best to treatment.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Moat
top 22%Funding
top 36%Market
top 50%Talent
bottom 49%Global
bottom 36%Moat: Editorial + unicorn rating 8/10 · Soonicorn
Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series D (May 2026)
Market: 45 employees (top 39% of Life Sciences)
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- May 2025Series C$21.8M
- May 2021Series C$70M
Founders & team
Investors
Pathology Asia Holdings
Funding & investor landscape
$112.1Btotal disclosed funding
1,702companies funded
7,030disclosed rounds
27rounds last 90 days
Most active investors
Notable founders
Bob Ragusa
Chief Executive Officer · GRAIL
Jim Collins
Co-Founder · Senti Bio
Wilson Wong
Co-Founder · Senti Bio
Matt Jacobson
Co-Founder · Terremoto
Jack Taunton
Co-Founder · Terremoto
Fred Manby
Co-Founder & CTO · Iambic Therapeutics
Thomas Miller
Co-Founder & CEO · Iambic Therapeutics
Daniel Getts
Co-Founder & CEO · CREATE Medicines
Amirali Talasaz
Co-founder and Co-Chief Executive Officer · Guardant Health
Roberto Mignone
Board of Directors · Guardant Health
Manish Agarwal
Co-Founder · Adela
Scott Bratman
Co-Founder · Adela
Prism market signals · United States · country-scoped Prism corpus, 1,572,524 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Oncology & Cancer Therapeutics is moving in the United States
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 12,968 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 52% → 67% across 2008–2026.
top research entities
- Harvard University573
- The University of Texas MD Anderson Cancer Center559
- Dana-Farber Cancer Institute413
- Johns Hopkins University356
- Cornell University352
leading researchers
Yang Liu · Yu Zhang · Hinda Najem · Wenxue Ma · Yan-Ruide Li · Murad Novruzov · Waseem Ullah Khan · Ullah Khan Inam
▲
Breakthroughs4,499 · 35%
▲ 32%→35% share
▲1.1× share momentum0 median citations90% since 2021mostly methods-led
Tumor microenvironment research is surging — US breakthrough papers rose from 124 to 1,921.
rising sub-themes (early→recent)
- Tumor microenvironment124→1921
- Immune system80→1464
- Immunotherapy66→1342
- Cancer research197→1345
- Cancer immunotherapy35→714
Newly emergingFlow cytometry 0→48 · Gene 0→45 · Hepatocellular carcinoma 0→42
Landmark Cancer immunotherapy using checkpoint blockade · 6,497 cites
◆
Advancements5,898 · 45%
▲ 44%→46% share
▲1.0× share momentum1 median citations89% since 2021mostly empirical
Cancer immunotherapy advancements are intensifying — US advancement papers scaled from 73 to 718.
rising sub-themes (early→recent)
- Tumor microenvironment212→2712
- Immune system142→2161
- Immunotherapy146→1778
- Cancer research238→1815
- Cancer immunotherapy73→718
Newly emergingBiomarker 0→106 · Epigenetics 0→82 · Gene 0→54
Landmark The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression · 4,937 cites
▼
Concerns1,469 · 11%
▼ 13%→11% share
▼0.8× share momentum3 median citations85% since 2021mostly reviews
Immunotherapy safety concerns are mounting — related concern papers grew from 42 to 624.
rising sub-themes (early→recent)
- Immunotherapy42→624
- Tumor microenvironment65→585
- Immune system31→529
- Cancer immunotherapy27→298
- Cancer research49→277
Newly emergingOvarian cancer 0→30 · Immunogenicity 0→27 · Transcriptome 0→26
Landmark A framework for advancing our understanding of cancer-associated fibroblasts · 3,630 cites
RESEARCH HOTSPOTS · United States
Where oncology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston1020 · +0.56
New York829 · +0.56
SF Bay Area480 · +0.57
Chicago409 · +0.54
Philadelphia355 · +0.57
Los Angeles275 · +0.59
San Diego274 · +0.59
Pittsburgh235 · +0.55
Ann Arbor223 · +0.63
Atlanta204 · +0.54
PATENT SIGNAL · United States
Who's filing oncology patents in the United States
United States oncology patent filing is accelerating — 2,574 filings from 797 assignees (2016–2025), led by Bristol Myers Squibb, IO Therapeutics, UNIV California; annual filings 108→277.
2,574 filings797 assigneespeak 362/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Bristol Myers Squibb105
- IO Therapeutics91
- UNIV California88
- DANA Farber Cancer INST87
- Memorial Sloan Kettering Cancer 74
- Baylor College Medicine63
- UNIV Texas61
- Massachusetts INST Technology47
Common questions
How many Oncology companies are there in United States?
Radar tracks 2665 indexable Oncology companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in United States?
The Oncology companies in United States on this list have raised a combined $112.1B in disclosed equity funding across 1702 funded companies.
Which is the highest-funded Oncology company in United States?
Moderna is the highest-funded Oncology company in United States, with $2.8B in disclosed equity funding.
How many Oncology companies in United States are funded?
1702 of the 2665 Oncology companies in United States on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in United States?
8 Oncology companies in United States on this list are valued at $1B or more.
Who are the top investors in United States Oncology companies?
The most active investors in United States Oncology companies on this list include HHS, Orbimed, RA Capital Management, Alexandria, NIH.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.